See more : Codere, S.A. (0SYQ.L) Income Statement Analysis – Financial Results
Complete financial analysis of Idorsia Ltd (IDRSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Idorsia Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Grupo Pochteca, S.A.B. de C.V. (POCHTECB.MX) Income Statement Analysis – Financial Results
- Tongyu Heavy Industry Co., Ltd. (300185.SZ) Income Statement Analysis – Financial Results
- Zhejiang Heda Technology Co., Ltd. (688296.SS) Income Statement Analysis – Financial Results
- GTY Technology Holdings Inc. (GTYH) Income Statement Analysis – Financial Results
- WISeKey International Holding AG (WKEY) Income Statement Analysis – Financial Results
Idorsia Ltd (IDRSF)
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 152.39M | 97.10M | 35.35M | 71.76M | 23.82M | 60.62M | 158.09M | 0.00 |
| Cost of Revenue | 7.15M | 6.27M | 18.03M | 381.08M | 438.53M | 370.08M | 161.89M | 18.12M |
| Gross Profit | 145.24M | 90.84M | 17.32M | -309.32M | -414.71M | -309.47M | -3.81M | -18.12M |
| Gross Profit Ratio | 95.31% | 93.55% | 48.99% | -431.06% | -1,741.08% | -510.52% | -2.41% | 0.00% |
| Research & Development | 293.56M | 383.33M | 414.21M | 381.08M | 438.53M | 370.08M | 134.91M | 282.62M |
| General & Administrative | 380.02M | 509.03M | 233.67M | 63.00M | 66.44M | 60.64M | 30.95M | 40.20M |
| Selling & Marketing | 0.00 | 173.40M | 0.00 | 27.00M | 9.00M | 0.00 | -9.95M | 0.00 |
| SG&A | 380.02M | 509.03M | 233.67M | 90.00M | 66.44M | 60.64M | 21.01M | 40.20M |
| Other Expenses | -273.19M | 0.00 | 0.00 | 0.00 | -8.16M | -7.85M | -4.12M | 0.00 |
| Operating Expenses | 400.38M | 893.80M | 648.35M | 484.28M | 506.24M | 431.69M | 155.92M | 322.82M |
| Cost & Expenses | 407.53M | 900.07M | 648.35M | 484.28M | 506.24M | 431.69M | 165.97M | 322.82M |
| Interest Income | 16.11M | 48.00K | 6.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 20.67M | 17.17M | 27.94M | 9.05M | 8.16M | 0.00 | 0.00 | 13.37M |
| Depreciation & Amortization | 19.03M | 19.83M | 18.03M | 18.93M | 19.69M | 19.56M | 10.05M | 18.12M |
| EBITDA | -254.55M | -783.09M | -588.84M | -420.64M | -456.94M | -351.51M | 2.17M | -305.20M |
| EBITDA Ratio | -167.04% | -806.46% | -1,665.78% | -586.19% | -1,942.68% | -579.88% | 1.37% | 0.00% |
| Operating Income | -255.15M | -802.97M | -613.00M | -410.58M | -482.42M | -371.08M | -7.88M | -322.82M |
| Operating Income Ratio | -167.43% | -826.93% | -1,734.15% | -572.18% | -2,025.36% | -612.15% | -4.99% | 0.00% |
| Total Other Income/Expenses | -39.11M | -17.12M | -21.80M | -38.70M | -2.78M | -16.75M | -7.21M | -13.88M |
| Income Before Tax | -294.25M | -820.09M | -634.81M | -449.28M | -485.20M | -387.83M | -15.10M | -336.69M |
| Income Before Tax Ratio | -193.10% | -844.56% | -1,795.82% | -626.10% | -2,037.02% | -639.79% | -9.55% | 0.00% |
| Income Tax Expense | 3.67M | 7.81M | -210.00K | -4.16M | 9.45M | -314.00K | 186.00K | -2.05M |
| Net Income | -297.92M | -827.90M | -634.60M | -444.79M | -493.61M | -386.39M | -14.27M | -335.14M |
| Net Income Ratio | -195.50% | -852.60% | -1,795.23% | -619.85% | -2,072.33% | -637.42% | -9.03% | 0.00% |
| EPS | -1.67 | -4.67 | -3.77 | -3.11 | -3.71 | -3.06 | -0.12 | -2.81 |
| EPS Diluted | -1.67 | -4.67 | -3.77 | -3.11 | -3.71 | -3.06 | -0.12 | -2.78 |
| Weighted Avg Shares Out | 178.25M | 177.43M | 168.50M | 142.81M | 132.95M | 126.45M | 115.53M | 119.12M |
| Weighted Avg Shares Out (Dil) | 178.25M | 177.43M | 168.50M | 142.81M | 132.95M | 126.45M | 115.53M | 120.72M |
Swiss pharma firm Idorsia plans debt restructuring, job cuts
Idorsia enters into exclusive negotiations for global rights to aprocitentan
Idorsia's once-daily TRYVIO™ (aprocitentan) is now available in the U.S., advancing treatment options for millions of patients with difficult-to-control hypertension
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
Idorsia announces financial results for the first nine months of 2024
Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
Amended terms of Idorsia's 2024 convertible bonds become effective
Idorsia Ltd (IDRSF) Q2 2024 Earnings Call Transcript
Idorsia announces financial results for the first half 2024
Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call
Source: https://incomestatements.info
Category: Stock Reports